Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...

Eli Lilly slashed ... that the global GLP-1 market will expand at a compound annual growth rate (CAGR) of 21.6% from 2024 to 2030. Considering that the TAM for Zepbound is set to continue growing ...

First of all, I think Lilly's Zepbound strategy is brilliant. It should open up a larger market for the company's obesity drug. As James Zervos, chief operating officer with Obesity Action ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior ... in some way Novo Nordisk’s strategy to increase patients’ population ...

‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could overtake #Novo ... that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through investigating ...

Zepbound’s superior efficacy and strategic market expansion suggest ... and it seems that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...